USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$21.98B
Market Cap
18.42
P/E Ratio
26.38
EPS
$492.62
52 Week High
$266.98
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $2.6B |
| Total Revenue | $2.9B |
| Cost Of Revenue | $310M |
| Costof Goods And Services Sold | $310M |
| Operating Income | $1.4B |
| Selling General And Administrative | $542M |
| Research And Development | $481M |
| Operating Expenses | $1.2B |
| Investment Income Net | - |
| Net Interest Income | $156M |
| Interest Income | $199M |
| Interest Expense | $43M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $73M |
| Income Before Tax | $1.5B |
| Income Tax Expense | $344M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.2B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $1.6B |
| Ebitda | $1.7B |
| Net Income | $1.2B |
| Field | Value (USD) |
|---|---|
| Total Assets | $7.4B |
| Total Current Assets | $3.9B |
| Cash And Cash Equivalents At Carrying Value | $1.7B |
| Cash And Short Term Investments | $1.7B |
| Inventory | $158M |
| Current Net Receivables | $279M |
| Total Non Current Assets | $3.5B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $80M |
| Intangible Assets Excluding Goodwill | $80M |
| Goodwill | $32M |
| Investments | - |
| Long Term Investments | $1.5B |
| Short Term Investments | $1.6B |
| Other Current Assets | $170M |
| Other Non Current Assets | - |
| Total Liabilities | $920M |
| Total Current Liabilities | $738M |
| Current Accounts Payable | $6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $300M |
| Total Non Current Liabilities | $182M |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | $300M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $300M |
| Other Current Liabilities | $432M |
| Other Non Current Liabilities | $182M |
| Total Shareholder Equity | $6.4B |
| Treasury Stock | - |
| Retained Earnings | $7.2B |
| Common Stock | $800K |
| Common Stock Shares Outstanding | $49M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $1.3B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $73M |
| Capital Expenditures | $247M |
| Change In Receivables | - |
| Change In Inventory | -$47M |
| Profit Loss | - |
| Cashflow From Investment | $417M |
| Cashflow From Financing | -$1.3B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $1.2B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $2.6B |
| Total Revenue | $2.9B |
| Cost Of Revenue | $310M |
| Costof Goods And Services Sold | $310M |
| Operating Income | $1.4B |
| Selling General And Administrative | $542M |
| Research And Development | $481M |
| Operating Expenses | $1.2B |
| Investment Income Net | - |
| Net Interest Income | $156M |
| Interest Income | $199M |
| Interest Expense | $43M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $73M |
| Income Before Tax | $1.5B |
| Income Tax Expense | $344M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.2B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $1.6B |
| Ebitda | $1.7B |
| Net Income | $1.2B |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
United Therapeutics Corporation (UTHR) is an innovative biotechnology firm focused on developing and commercializing advanced therapies for serious chronic conditions, with a primary focus on pulmonary hypertension and organ transplantation. Headquartered in Silver Spring, Maryland, the company maintains a robust pipeline of therapies that leverage cutting-edge technologies to meet critical unmet medical needs, both domestically and globally. With a commitment to enhancing healthcare outcomes, United Therapeutics is strategically positioned for continued growth and impactful contributions to the life sciences sector.